EP Patent

EP1361220A1 — Cyclic compounds having thrombopoietin receptor agonism

Assigned to Shionogi and Co Ltd · Expires 2003-11-12 · 23y expired

What this patent protects

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X 1 ―Y 1 ―Z 1 wherein X 1 is optionally s…

USPTO Abstract

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X 1 ―Y 1 ―Z 1 wherein X 1 is optionally substituted aryl, optionally substituted heteroaryl or the like; Y 1 is -NR A CO-(CH 2 ) 0-2 - or the like (wherein R A is hydrogen atom or the like); and Z 1 is a cyclic group fused the same or different two ring selected from optionally substituted carbocyclic group and optionally substituted heterocyclic group.

Drugs covered by this patent

Patent Metadata

Patent number
EP1361220A1
Jurisdiction
EP
Classification
—
Expires
2003-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Shionogi and Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.